Blackrock Advisors Lowers stake in Pfizer (PFE)

Pfizer (PFE) : Blackrock Advisors reduced its stake in Pfizer by 1.3% during the most recent quarter end. The investment management company now holds a total of 51,266,613 shares of Pfizer which is valued at $1,793,306,123 after selling 677,519 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.Pfizer makes up approximately 1.87% of Blackrock Advisors’s portfolio.

Other Hedge Funds, Including , D L Carlson Investment Group Inc reduced its stake in PFE by selling 13,808 shares or 9.18% in the most recent quarter. The Hedge Fund company now holds 136,665 shares of PFE which is valued at $4,780,542. Pfizer makes up approx 1.63% of D L Carlson Investment Group Inc’s portfolio.Smith Chas P Associates Pa Cpas boosted its stake in PFE in the latest quarter, The investment management firm added 471 additional shares and now holds a total of 573,645 shares of Pfizer which is valued at $20,243,932. Pfizer makes up approx 3.37% of Smith Chas P Associates Pa Cpas’s portfolio.Hudson Canyon Investment Counselors boosted its stake in PFE in the latest quarter, The investment management firm added 2,140 additional shares and now holds a total of 13,680 shares of Pfizer which is valued at $504,108. Pfizer makes up approx 0.55% of Hudson Canyon Investment Counselors’s portfolio.Rs Investment Management Co reduced its stake in PFE by selling 851,960 shares or 51.79% in the most recent quarter. The Hedge Fund company now holds 793,005 shares of PFE which is valued at $29,222,234. Pfizer makes up approx 0.29% of Rs Investment Management Co’s portfolio.

Pfizer closed down -0.21 points or -0.60% at $34.98 with 1,95,68,121 shares getting traded on Friday. Post opening the session at $35.06, the shares hit an intraday low of $34.825 and an intraday high of $35.12 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *